Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Novartis Pharmaceuticals
Age
55–90
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
\- Active choroidal neovascular AMD in at least one eye.
You may not be if
Retinal disease other than AMD that, in the investigator's opinion, would interfere with safety or study conduct.
Choroidal neovascularization due to a cause other than AMD.
In the study eye, media opacity that, in the investigator's opinion, would interfere with study conduct.
Any disease or concomitant (or recent) medication expected to cause systemic immunosuppression.
History of meningococcal meningitis in the past 10 years, or any history of recurrent meningitis.
History of hospitalization for pneumococcal pneumonia within the past 3 years.
History of serious systemic infection within the past 12 months.
Any of the following treatments to the study eye within 7 days prior to study drug dosing: ranibizumab (Lucentis), bevacizumab (Avastin), pegaptanib (Macugen), or other VEGF inhibitor.
